Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I. Sherman

Showing results (41-50 of 141) with videos related to

Pageof 15
Sort By:
Molecular Cancer Research : MCR|December 16, 2018
Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid CancerRozita Bagheri-Yarmand, Krishna M Sinha, Ling Li, et al.
Surgery|December 12, 2003
Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patientsTina W F Yen, Suzanne E Shapiro, Robert F Gagel, et al.
Thyroid : Official Journal of the American Thyroid Association|July 25, 2008
Four patients with cutaneous metastases from medullary thyroid cancerLibero Santarpia, Adel K El-Naggar, Steven I Sherman, et al.
The Journal of Clinical Endocrinology and Metabolism|April 6, 2006
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoidesFarah Ghori, Kristel D Polder, Lauren C Pinter-Brown, et al.
Diabetes Care|December 28, 2017
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER TrialLaszlo Hegedüs, Steven I Sherman, R Michael Tuttle, et al.
Human Pathology|October 24, 2007
Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratificationDanielle D Elliott, Steven I Sherman, Naifa L Busaidy, et al.
Archives of Otolaryngology--Head & Neck Surgery|February 23, 2011
Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancerMauricio A Moreno, Garima Agarwal, Rolando de Luna, et al.
Endocrine-Related Cancer|August 17, 2022
Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancersMarie-Claude Hofmann, Muthusamy Kunnimalaiyaan, Jennifer R Wang, et al.
JAMA Otolaryngology-- Head & Neck Surgery|November 27, 2024
Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid CarcinomaSophie Li, Guibin Zheng, Li Xu, et al.
The Lancet. Oncology|July 28, 2016
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trialMarcia S Brose, Maria E Cabanillas, Ezra E W Cohen, et al.
Pageof 15

Showing results (41-50 of 141) with videos related to

Sort By:
Pageof 15
Molecular Cancer Research : MCR|December 16, 2018
Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid CancerRozita Bagheri-Yarmand, Krishna M Sinha, Ling Li, et al.
Surgery|December 12, 2003
Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patientsTina W F Yen, Suzanne E Shapiro, Robert F Gagel, et al.
Thyroid : Official Journal of the American Thyroid Association|July 25, 2008
Four patients with cutaneous metastases from medullary thyroid cancerLibero Santarpia, Adel K El-Naggar, Steven I Sherman, et al.
The Journal of Clinical Endocrinology and Metabolism|April 6, 2006
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoidesFarah Ghori, Kristel D Polder, Lauren C Pinter-Brown, et al.
Diabetes Care|December 28, 2017
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER TrialLaszlo Hegedüs, Steven I Sherman, R Michael Tuttle, et al.
Human Pathology|October 24, 2007
Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratificationDanielle D Elliott, Steven I Sherman, Naifa L Busaidy, et al.
Archives of Otolaryngology--Head & Neck Surgery|February 23, 2011
Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancerMauricio A Moreno, Garima Agarwal, Rolando de Luna, et al.
Endocrine-Related Cancer|August 17, 2022
Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancersMarie-Claude Hofmann, Muthusamy Kunnimalaiyaan, Jennifer R Wang, et al.
JAMA Otolaryngology-- Head & Neck Surgery|November 27, 2024
Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid CarcinomaSophie Li, Guibin Zheng, Li Xu, et al.
The Lancet. Oncology|July 28, 2016
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trialMarcia S Brose, Maria E Cabanillas, Ezra E W Cohen, et al.
Pageof 15